In 2024, the pharmaceutical company PrJSC Darnitsa (Kyiv) registered 10 drugs abroad and entered the markets of six new countries.

As the company reports in a press release, in particular, the new markets opened last year were the EU countries, Bosnia and Herzegovina, Israel, New Zealand, and Malaysia.

Darnitsa entered these markets with drugs for the treatment of heart failure, acute and chronic renal failure, nephrotic syndrome, liver diseases and arterial hypertension, treatment and prevention of candidal infections, treatment and prevention of acute inflammatory diseases of the oral cavity and throat, as well as a drug for the systemic treatment and prevention of infectious diseases.

As reported, Darnitsa plans to release 62 new brands of drugs by 2029, including 43 brands of its own production and 19 under licensing. During 2024, it launched 13 new drugs on the market.

According to the results of 2023, Darnitsa increased its export share to 4%. The company exports products to 17 countries. At the same time, since 2015, Darnitsa stopped exporting to the Russian Federation, and after February 24, 2022 - to Belarus.

According to the results of 2023, Darnitsa increased its net income from core activities by 32.8% compared to 2022 - to UAH 6.969 billion.

Darnitsa is the leader of the Ukrainian pharmaceutical market in physical terms. The company has been present on the market for over 90 years and produces medicines of 180 brands in 15 different forms. Strategic areas of portfolio development are cardiology, neurology, and pain management. According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Hlib Zahoriy.